Etoposide phosphate (BMY-40481)

Description

APIM050404: Etoposide phosphate (BMY-40481) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester prodrug of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest, apoptosis, and autophagy.

CAS No.: 117091-64-2
IUPAC/Chemical Name: [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate
Molecular Formula: C₂₉H₃₃O₁₆P
Molecular Weight: 668.54
Purity: 99% (HPLC)
QC: LC/MS, 1HNMR
Solubility: Soluble in DMSO and water
Storage: Store at 0 °C (short term), -20 °C (long term), Desiccated
Note: Please contact us for COA, Spectra, and SDS information.

Background Information:

Etoposide phosphate (BMY-40481) (CAS No.: 117091-64-2), a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Target: Topoisomerase II

IC₅₀: 0.945 μM (HCT116 FBXW+/+), 0.375 μM (HCT116 FBXW-/-), and 1.437 μM (HCT116 p53-/-)

In Vitro: Etoposide phosphate is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4′ of the E ring of the etoposide molecule.[1]
Etoposide phosphate (0-1 μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC₅₀ values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively.[2]
Etoposide phosphate (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells.[2]

In Vivo: Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8 in female CD-1 mice.[3]

What is the solubility of Etoposide phosphate (BMY-40481) in vitro?
125 mg/mL in H₂O (Need ultrasonic)

Reference:
[1]. Witterland, A. H. et al. “Etoposide Phosphate, the Water Soluble Prodrug of Etoposide”, Pharm. World Sci. 1996, 18, 163-170.
[2]. Cui, D. et al. “FBXW7 Confers Radiation Survival by Targeting p53 for Degradation”, Cell Rep. 2020, 30, 497-509.
[3]. Bregman, C. L. et al. “Etoposide- and BMY-40481-Induced Sensory Neuropathy in Mice”, Toxicol. Pathol. 1994, 22, 528-535.
[4]. Millward, M. J. et al. “Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)”, Eur. J. Cancer 1995, 31, 2409-2411.
[5]. Doyle, T. W. et al. “Second generation analogs of etoposide and mitomycin C”, Cancer Treat. Rev. 1990, 17, 127-131.
[6]. Saulnier, M. G. et al. “E-ring desoxy analogs of etoposide”, J. Med. Chem. 1989, 32, 1418-1420.
[7]. Saulnier, M. G. et al. “Synthesis of etoposide phosphate, BMY-40481: A water-soluble clinically active prodrug of etoposide”, Bioorg. Med. Chem. Lett. 1994, 4, 2567-2572.

Frequent questions related to “Etoposide Phosphate (BMY-40481) (CAS 117091-64-2), a Potent Anti-Cancer Chemotherapy Agent and a Selective Topoisomerase II Inhibitor”:

Does Etoposide Phosphate bind mouse Topoisomerase II?
Who makes Etoposide Phosphate?
What is Etoposide Phosphate?
What is the mechanism of action for Etoposide Phosphate?

Popular searches related to “Etoposide Phosphate (BMY-40481) (CAS 117091-64-2), a Potent Anti-Cancer Chemotherapy Agent and a Selective Topoisomerase II Inhibitor”:

Etoposide Phosphate results
Etoposide Phosphate fda approval
Etoposide Phosphate mechanism of action
Etoposide Phosphate price
Etoposide Phosphate side effects
Etoposide Phosphate Inhibitor
Etoposide Phosphate synthesis
Etoposide Phosphate analogue
BI-3406 structure activity study
Etoposide Phosphate in vitro
Etoposide Phosphate in vivo
Etoposide Phosphate supplier
Etoposide Phosphate clinical study
Etoposide Phosphate Topoisomerase II
Etoposide Phosphate Topoisomerase II inhibitor
Etoposide Phosphate Cytotoxicity
Etoposide Phosphate Target
Etoposide Phosphate Inhibitor
Topoisomerase II Inhibitor
Topoisomerase II
BMY-40481
BMY40481
 

Additional information

Size	100 mg, 25 mg

No more offers for this product!